- Home
- EVMN vs ESPR Comparison
EVMN vs ESPR Comparison
Compare EVMN & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVMN | ESPR |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.9M | 660.1M |
| IPO Year | 2025 | 2013 |
Fundamental Metrics
Financial Performance| Metric | EVMN | ESPR |
|---|---|---|
| Price | $21.90 | $3.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $39.33 | $6.86 |
| AVG Volume (30 Days) | 92.4K | ★ 7.0M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,000,000.00 | ★ $303,802,000.00 |
| Revenue This Year | N/A | $25.45 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 40.00 | 2.83 |
| 52 Week Low | $16.70 | $0.69 |
| 52 Week High | $24.03 | $4.03 |
Technical Indicators
Market Signals| Indicator | EVMN | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 63.61 |
| Support Level | N/A | $3.59 |
| Resistance Level | N/A | $3.91 |
| Average True Range (ATR) | 0.00 | 0.24 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 0.00 | 77.74 |
Price Performance
Historical ComparisonAbout EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.